Pacific Biosciences of California, Inc. (PACB) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: improvements in gross margins and reduced operating expenses are positives, but declines in Americas and Asia Pacific revenues are concerning. The Q&A highlights temporary challenges in Vega placements and strategic moves towards clinical applications. While there is optimism about future growth, particularly in EMEA and China, the lack of specific guidance and ongoing challenges in academic funding temper expectations. This balance of positive and negative factors suggests a neutral short-term stock price movement.
Key Financial Performance
Revenue $38.4 million in Q3 2025, a decrease from $40 million in Q3 2024 (4% decrease). The decline was due to fewer Vega shipments in Europe and lower ASPs, partially offset by record consumable revenue.
Consumable Revenue $21.3 million in Q3 2025, a 15% increase year-over-year. This growth was driven by broad adoption of SPRQ Chemistry and increased utilization across the installed base.
Non-GAAP Gross Margin 42% in Q3 2025, up from 33% in Q3 2024. The improvement was due to a higher mix of consumables, lower manufacturing costs for Vega systems, and improved Revio SMRT Cell manufacturing yields.
Instrument Revenue $11.3 million in Q3 2025, a 33% decrease year-over-year. The decline was driven by lower Revio unit shipments, partially offset by Vega system shipments.
Service and Other Revenue $5.8 million in Q3 2025, a 25% increase year-over-year. The growth was driven by an increase in Revio service contract revenue.
EMEA Revenue $10.7 million in Q3 2025, an 18% increase year-over-year. The growth was driven by a 50% increase in consumable revenue, partially offset by lower Vega placements.
Americas Revenue $18.1 million in Q3 2025, a 10% decrease year-over-year. The decline was due to reduced academic capital spending and elongated procurement cycles.
Asia Pacific Revenue $9.6 million in Q3 2025, an 11% decrease year-over-year. The decline was due to fewer Revio placements, partially offset by higher consumable revenue.
Non-GAAP Operating Expenses $53.9 million in Q3 2025, a 14% decrease year-over-year. The reduction was due to restructuring initiatives and lower non-cash stock-based compensation.
Non-GAAP Net Loss $36.8 million in Q3 2025, compared to $46 million in Q3 2024 (20% improvement). The improvement was due to reduced operating expenses and higher gross margins.
Cash Burn $16 million in Q3 2025, an improvement from prior quarters. The improvement was attributed to restructuring, gross margin improvements, and expense discipline.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Revio and Vega Systems: Shipped 13 Revio systems and 32 Vega systems in Q3, bringing cumulative shipments to 310 and 105 systems, respectively. Approximately 75% of Revio shipments were to new customers. Vega shipments were below forecast, particularly in Europe, but 60% of placements went to new customers.
SPRQ-Nx Chemistry: Unveiled new SPRQ-Nx chemistry, expected to lower the cost of human genome sequencing to less than $300 per genome at scale. Beta testing to begin in 2026 with over 100 customers interested.
PureTarget Portfolio: Launched enhanced PureTarget portfolio, including panels for carrier screening and neurological diseases. Designed to replace multiple tests with one workflow.
EMEA Growth: EMEA revenue grew 18% year-over-year in Q3, driven by a 50% increase in consumable revenue.
China Market: Sequel II CNDx system received Class III Medical Device Registration approval in China, marking the first clinical-grade long-read sequencer approval globally. Berry Genomics plans to launch the system for thalassemia testing and expand to other assays.
Large-Scale Studies: HiFi technology selected for major projects like the Korean Pangenome Reference Project and the NIH-funded long-life family study, showcasing its utility in population-scale genomics.
Consumable Revenue: Achieved record consumable revenue of $21.3 million in Q3, a 15% year-over-year increase. Revio annualized pull-through was $236,000 per system.
Cash Burn Reduction: Reduced cash burn to $16 million in Q3, with a total expected cash burn of $115 million for 2025, a $70 million improvement from 2024.
Gross Margin Improvement: Non-GAAP gross margin reached 42%, the highest since 2022, driven by improved product mix and manufacturing efficiencies.
Clinical Applications: Focus on expanding HiFi sequencing in clinical settings, including partnerships with Berry Genomics and Children's Mercy Hospital for genetic disease diagnosis.
Cost Reduction Strategy: SPRQ-Nx chemistry and multi-use SMRT Cells aim to reduce sequencing costs and improve gross margins, supporting broader adoption.
Population Genomics: HiFi technology is being integrated into large-scale studies to uncover genetic diversity and improve precision medicine.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Miss: Revenue for Q3 2025 came in below expectations at $38.4 million, primarily due to fewer Vega shipments in Europe and lower-than-expected ASPs.
Funding Challenges in Americas: The funding environment in the Americas remains challenging, particularly for academic and government research customers dependent on NIH and public budgets, leading to elongated procurement cycles.
Asia Pacific Funding Environment: The funding environment in Asia Pacific continues to be challenging, impacting revenue performance.
Lower ASPs: Revio systems were placed with key institutions at lower prices, resulting in lower ASPs for the quarter.
Vega Shipments in Europe: Several Vega instruments were stuck in procurement processes in Europe, delaying shipments and impacting revenue.
Cash Burn: Despite improvements, the company still reported a cash burn of $16 million in Q3 2025, with a total expected cash burn of $115 million for the year.
Restructuring Costs: The company is undergoing restructuring, which has led to reduced headcount and operating expenses but may pose short-term operational challenges.
Dependence on Consumables: The company’s revenue growth is heavily reliant on consumables, which may pose risks if demand fluctuates.
Regulatory and Market Risks in China: While the company received regulatory approval for the Sequel II CNDx system in China, reliance on this market introduces risks tied to regulatory and market dynamics.
Competitive Pressures: The company faces competitive pressures in the sequencing market, particularly as it works to lower costs and improve technology adoption.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for Q4 2025: The company expects total fourth-quarter revenue to grow both year-over-year and quarter-over-quarter, with approximately 10% sequential growth.
Full-Year 2025 Revenue Guidance: Revenue guidance for the full year of 2025 has been narrowed to the low end of the range, now expected to be between $155 million to $160 million.
Cash Burn Guidance for 2025: Total cash burn for 2025 is expected to be approximately $115 million, an improvement of more than $70 million compared to 2024.
Cash Flow Breakeven Target: The company aims to achieve cash flow breakeven by the end of 2027.
New Chemistry Launch (SPRQ-Nx): The SPRQ-Nx chemistry is expected to dramatically lower the cost of human genome sequencing to less than $300 per genome at scale. Beta testing will begin later this month, with early access in 2026 and full rollout planned for 2026.
Revio and Vega Instrument Shipments: The company expects to ship more Revio and Vega instruments in Q4 2025 than in any other quarter this year.
Consumables Revenue Growth: Consumables revenue grew 15% year-over-year in Q3 2025, and the company anticipates continued strength in this segment.
Clinical Market Expansion: The company is focused on penetrating the clinical market and expanding opportunities into large population-scale programs.
New Product Launches: The company plans to launch multi-use SMRT Cells for Revio in 2026, which will reduce sequencing costs and improve gross margins.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Why were Revio ASPs lower this quarter, and what is the expectation for the next quarter?
A:Revio ASPs were lower this quarter due to strategic placements into accounts with lower ASPs but high throughput, which is expected to drive better consumable usage and revenue. ASPs are expected to recover in the fourth quarter.
Q:What caused the shortfall in Vega placements, and what is the outlook for the next quarter?
A:The shortfall in Vega placements was due to procurement challenges in Europe, with about half a dozen instruments delayed. Some of these have already been processed and are expected to ship in Q4. The issue is considered temporary.
Q:What contributed to the stronger-than-expected gross margin this quarter?
A:The stronger gross margin was driven by product mix, record consumable sales, cost reductions in SMRT Cell manufacturing, and lower production costs for Vega and Revio systems. Tariffs on the Vega system had minimal impact.
Q:What is the outlook for the funding environment in 2026?
A:The funding environment is expected to remain challenging, particularly in the academic sector. However, the company is pivoting to clinical applications, which have more robust funding and are showing strong traction.
Q:What is the expected pull-through for Vega and Revio systems?
A:Vega pull-through is estimated to be between $25,000 and $45,000 annually, but the company will provide more details next year. Revio pull-through is at the higher end of targets, with steady utilization across the installed base.
Q:What are the benefits and expectations for the SPRQ-Nx chemistry?
A:SPRQ-Nx aims to drive revenue growth and improve gross margins by allowing multiple uses of SMRT Cells. Early feedback indicates consistent data fidelity and high-quality results. Over 100 customers have expressed interest, and a beta program is underway.
Q:What are the potential applications for PureTarget HiFi assays?
A:PureTarget HiFi assays are used for carrier screening, single-gene tests, and other difficult-to-sequence genomes. They are driving Revio placements in clinical accounts and are expected to contribute to revenue growth in 2026.
Q:How has the funnel for population-scale programs evolved?
A:The funnel is expanding, with new opportunities arising since the ASHG announcement. Some programs are expected to close soon, potentially driving significant growth.
Q:What is the geographic distribution of Revio placements and consumable sales?
A:Revio placements are balanced globally, with strong growth in Europe. Most placements are in commercial and clinical accounts rather than NIH-funded environments.
Q:What is the impact of the U.S. government shutdown on order volumes?
A:The shutdown has not had a material impact so far, as the company's revenue is less dependent on U.S. government funding. However, a prolonged shutdown could affect future quarters.
Q:What is the company's approach to rolling out SPRQ-Nx?
A:The rollout is measured, starting with a beta program and early access phase. Single-use SMRT Cells will still be available alongside multi-use cells. The focus is on growing consumable revenue.
Q:What is the outlook for revenue growth in 2026?
A:The company expects growth in 2026, driven by increased instrument placements, consumable sales, and clinical applications. Formal guidance will be provided later.
Q:What is the impact of the China market on the company's growth?
A:China remains a strong market, with high utilization rates and opportunities in clinical applications. The removal of the Illumina ban may ease business risks and create additional opportunities.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance on gross margin for 2026, Vega pull-through targets for this year, and detailed revenue growth expectations for 2026. They also did not specify the number of beta testers for SPRQ-Nx or the exact impact of the U.S. government shutdown on future quarters.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ASPs
CNDx system
Compatible program
Consortium study
EMEA increase
Fiber seq
Human
II CNDx
LongPlex
National Institute
Pangenome Reference
PureTarget portfolio
SMRT Cell
SPRQ Nx
Sequel II
access
accuracy testing
assay
atrophy
carrier
demand
disorder
family
placement
precision
repeat
scale study
screening
sequence
strength
thalassemia
type
use
win
workflow
PACB Transcript
Pacific Biosciences of California, Inc. (PACB) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call highlights a strong financial performance with a 25% YoY revenue increase and improved gross margins. Despite operating expenses rising, the net loss decreased, signaling better financial health. The absence of strategic updates or shareholder return plans is neutral, while the forward-looking risk acknowledgment is typical. Overall, the positive financial results and reduced losses suggest a positive stock reaction.
Pacific Biosciences of California, Inc. (PACB) Q4 2025 Earnings Call Transcript
Positive2-14
The earnings call indicates strong product development and market expansion, with optimistic guidance for revenue growth and cost reduction. Despite some uncertainties in management responses, the focus on clinical market penetration, new product launches, and cost-effective sequencing solutions suggests positive sentiment. The Q&A section supports this with expected growth in international markets and operational efficiencies. The positive outlook on revenue and consumable growth, coupled with strategic cost management, outweighs any negative aspects, leading to a positive stock price prediction.
Pacific Biosciences of California, Inc. (PACB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
Pacific Biosciences of California, Inc. (PACB) Q3 2025 Earnings Call Transcript
Unknown11-5
The earnings call presents a mixed picture: improvements in gross margins and reduced operating expenses are positives, but declines in Americas and Asia Pacific revenues are concerning. The Q&A highlights temporary challenges in Vega placements and strategic moves towards clinical applications. While there is optimism about future growth, particularly in EMEA and China, the lack of specific guidance and ongoing challenges in academic funding temper expectations. This balance of positive and negative factors suggests a neutral short-term stock price movement.
PACB Slides
PACB Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
